Direct answer: Corvian Advisory provides sell-side, buy-side, financial due diligence and business valuation for China-related M&A. We advise on SAFE foreign exchange approvals, MOFCOM anti-monopoly filings, VIE structure assessment and UAE–China cross-border structuring. Minimum deal size: CNY 10M (~AED 5M / USD 1.4M). The UAE is an increasingly important hub for Chinese outbound capital and a structuring gateway for GCC investors accessing Chinese assets.
Six specialist services built for the regulatory and commercial complexity of China-related M&A, from SAFE-compliant cross-border structuring to CAS/IFRS financial due diligence and VIE assessment.
Full sell-side process management for Chinese business owners targeting UAE, GCC or international acquirers. We prepare the IM, coordinate MOFCOM approvals, and manage the SPA process to closing. Focus on clean energy, manufacturing, logistics and technology.
We act for UAE and GCC investors acquiring Chinese businesses, target identification, structure selection (WFOE, JV, HK SPV), SAFE pre-assessment and MOFCOM filing support. We pre-screen negative list sectors before mandate commitment.
Buy-side FDD under CAS with IFRS reconciliation, QoE, normalised EBITDA, working capital, net debt, and related-party transactions. We assess PRC tax position, VAT, social insurance underpayment and VIE enforceability.
Strategic pre-sale advisory mapping MOFCOM, SAFE and CSRC implications from day one, WFOE vs JV vs HK SPV structuring, and cross-border repatriation and tax treaty application.
Specialist structuring for UAE–China corridors: HK SPV structures, SAFE Circular 37 registration, ODI registration, and UAE CT implications of Chinese subsidiary income, using JAFZA/DMCC as structuring hubs.
VIE structures are common in Chinese businesses with offshore listings or foreign ownership restrictions. We assess enforceability, conversion risk, and unwinding strategies for acquirers seeking direct WFOE ownership.
China M&A demands a rare combination: deep financial due diligence skills, multi-regulator navigation (SAFE, MOFCOM, CSRC, NDRC) and cross-border structuring expertise. Corvian delivers all three, with UAE market credibility that matters to Chinese counterparties.
All cross-border CNY/USD flows require SAFE registration or approval. We manage Circular 37 offshore registration and inbound/outbound capital account procedures as part of every China mandate.
Founder-family related-party transactions are pervasive in Chinese SMEs. Our FDD dissects RPT flows, preferential pricing, and undisclosed liabilities for a clean QoE picture.
VIE structures in restricted sectors carry enforcement risk. We assess contractual control strength, conversion pathway, and model WFOE conversion timeline and cost for buyer pricing.
Hong Kong companies provide common law protection, HKD/USD settlement, and simpler capital mobility. We advise on HK holdco use, stamp duty and mainland regulatory interfaces.
The UAE hosts 5,000+ Chinese businesses and serves as the primary Chinese outbound investment hub for the GCC and Africa. JAFZA/DMCC concentration makes UAE-to-China deal sourcing unusually productive.
PRC CIT is 25% standard (15% for HNTE status). VAT compliance, underpaid social insurance and deferred tax positions are standard FDD items we model for buyer pricing.
China's domestic M&A market remains large but highly regulated. Inbound foreign investment is subject to the Negative List, sectors where foreign ownership is restricted or prohibited. Mid-market transactions in manufacturing, clean energy, consumer goods and technology have seen sustained activity.
Chinese outbound M&A has rebounded post-2022, with UAE increasingly positioned as the primary non-Western M&A corridor. Chinese companies use UAE holding structures to access GCC markets, manage USD settlement and reduce regulatory friction for third-country investments.
BRI-related investment continues to flow through UAE infrastructure, JAFZA is a major logistics hub for BRI corridor activity. UAE–China bilateral trade exceeds AED 200B annually. Abu Dhabi sovereign entities (ADIA, Mubadala) have significant China allocations.
Standard PRC CIT is 25%. HNTE status reduces CIT to 15%, a key valuation input validated in FDD. Dividend WHT: 10% for non-treaty investors; 5% via Hong Kong DTA (substance required). VAT: 6–13%. Social insurance underpayment is a common hidden liability in smaller Chinese businesses.
| Sector | EV/EBITDA | Key Drivers |
|---|---|---|
| New Energy Vehicles (NEV) | 15–35× | Battery tech, supply chain, export growth |
| Solar / Renewable Energy | 10–20× | Global capacity leadership, contracted revenue |
| Technology / SaaS | 12–25× | ARR, user base, domestic moat |
| Healthcare / Biopharma | 10–22× | NMPA approvals, pipeline, demographics |
| Industrial Automation | 8–18× | Robotics, precision manufacturing, IP |
| Cross-Border Logistics | 7–14× | BRI corridor, e-commerce fulfilment |
| Consumer Goods / Retail | 7–13× | Brand, distribution, premiumisation |
| Financial Technology | 10–20× | Regulatory licence, TPV, margins |
PRC CIT: 25% standard; 15% HNTE status (requires R&D spend, validate in FDD). Dividend WHT: 10% standard; 5% via HK DTA. MOFCOM anti-monopoly threshold: global combined turnover CNY 10B + China turnover CNY 400M, or China market share ≥25%. SAFE ODI registration required for all outbound Chinese investment. Negative List sectors restrict foreign ownership, VIE structure often used as workaround.
IVS-compliant valuations using A-share, H-share and global comparables, normalised CAS/IFRS EBITDA, and precedent transaction multiples from China deal databases. All cross-border mandates include AED/USD equivalent output.
Benchmarked against A-share, H-share and US-listed Chinese comparables, adjusted for size, listing liquidity, HNTE status and CAS/IFRS EBITDA normalisation.
5–7 year projection under CAS, WACC calibrated to PRC market risk premiums and offshore discount rate. HNTE renewal risk modelled, relevant for NEV/cleantech.
China precedent multiples from domestic and cross-border deal databases. Control premiums typically 30–50% over public multiples due to regulatory execution risk.
Post-acquisition allocation of purchase price to identifiable intangibles (customer relationships, technology, brand, non-compete) and goodwill for IFRS consolidated accounts.
For asset-heavy businesses and holding entities. Restated fair values under IFRS 13/IVS with PRC land use rights assessed separately (time-limited, not freehold).
VIE structures carry an enforceability/conversion risk discount vs WFOE direct ownership. We model haircuts based on sector and regulatory posture, typically 10–25%.
A five-stage process designed for the regulatory sequencing of China M&A, with SAFE, MOFCOM and sector approvals parallel-tracked to manage timeline.
Negative list assessment, structure selection (WFOE, JV, HK SPV), VIE pre-assessment, MOFCOM threshold check, SAFE pre-assessment.
CAS/IFRS FDD. QoE, related-party analysis, tax exposure, HNTE validation. Valuation report in CNY and AED/USD.
MOFCOM notification, NDRC ODI registration, SAFE remittance registration, sector approvals (CBIRC, CSRC).
SPA under PRC or HK law. Representations, warranties, tax indemnities. Locked-box completion mechanism.
SAFE-approved fund transfer, WFOE/JV registration update (SAMR), IFRS 3 PPA advisory, UAE CT treatment.
All fees quoted in CNY with AED equivalent. Minimum deal size CNY 10M (~AED 5M / USD 1.4M).
Financial due diligence and valuation are fixed-fee or capped-fee, agreed upfront. M&A advisory fees are also agreed upfront, in writing, before work begins.
SAFE, MOFCOM and sector-specific regulatory advisory is scoped per mandate, regulatory complexity varies by sector and deal structure.
All mandates include a complimentary 30-minute discovery call to assess feasibility and provide a precise fee estimate before any engagement letter is signed.
CAS/IFRS reconciliation, QoE, related-party review, working capital, net debt, PRC tax, HNTE validation, VIE assessment. 4–8 weeks. (~AED 24,000–168,000)
Fees agreed upfront. Full process management from mandate to close, structure advisory, regulatory filing support, negotiation and SPA coordination.
IVS-compliant. DCF + EV/EBITDA + precedent transactions. CNY and AED/USD output. IFRS 3 PPA from CNY 70,000. 2–4 weeks. (~AED 17,000–96,000)
A China-side transaction involving a GCC counterparty needs someone fluent on both ends: SAFE and MOFCOM filing requirements on the China side, and the buyer or seller expectations of a UAE or Gulf principal on the other. Generalist advisors typically cover one side well and the other by referral. We run both directly, senior-led, with fees agreed upfront, and no handoff to a junior team once the mandate is signed.
A Shanghai manufacturing exporter's sale to a GCC strategic acquirer, following CAS/IFRS reconciliation and related-party normalisation. Company name withheld.
Buy-side target search and SAFE/MOFCOM filing coordination for a UAE group's acquisition of a Shenzhen technology supplier, plus a related Hong Kong SPV structuring engagement. Deal terms not disclosed.
Direct answers to what clients ask most about M&A advisory for China transactions and the UAE–China corridor.
"Corvian's SAFE pre-assessment saved us from a deal that would have faced serious fund transfer restrictions. They identified the regulatory issue at week two, before we had incurred significant FDD costs. Their HK SPV structuring resolved the capital mobility issue entirely."
"The CAS/IFRS reconciliation work was eye-opening. Revenue recognition under CAS had overstated profitability by over 15% versus IFRS, Corvian's QoE analysis gave us the real earnings base and we renegotiated the price accordingly."
"We needed to understand the VIE discount for a Chinese education business we were considering. Corvian modelled the VIE enforceability risk and WFOE conversion timeline clearly, their 18% VIE haircut matched our legal counsel's independent assessment."
Whether selling a Chinese business to UAE/GCC buyers, or acquiring a Chinese target, we respond within 24 hours with a clear, no-obligation scope and fee.